Abstract
Following the Breakthrough Therapy Designation system in 2012 in the United States, the Sakigake Designation was introduced in 2015 in Japan, and PRIME (PRIority MEdicines) was started in 2016 in the European Union. Each system aims at giving patients better access to innovative drugs and regenerative medicine products by providing product developers with generous regulatory and scientific support from an early development stage. So far, the designation systems have operated independently in each region, and no products with the same indication have been designated commonly under the 3 designation systems. However, no designation system excludes a product designated under another system, which allows the possibility of an applicant to seek all 3 designations; this may happen in the near future. Therefore, an understanding of the current situation under each designation system will contribute to effective operation of each system as well as identification of further collaborative activities between the European Medicines Agency; Japan's Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency; and the United States Food and Drug Administration. Such collaborations can be successful because these organiza...Continue Reading
References
May 13, 2015·Clinical Therapeutics·Yasuto Otsubo
Jan 16, 2016·The Veterinary Record
Feb 13, 2016·Trials·Peter Doshi, Tom Jefferson
May 31, 2016·The Journal of Dermatology·Hidehisa SaekiMasafumi Iijima
Citations
Oct 15, 2019·Clinical Pharmacology and Therapeutics·Maggie LiuMazin Derzi
Mar 20, 2020·Internal Medicine·Akihide KonishiHaruki Shirato
Sep 4, 2019·Circulation·Andrew Plump, George Davey Smith
Oct 7, 2017·Clinical Pharmacology and Therapeutics·Delphi G M CoppensJarno Hoekman
May 8, 2018·Therapeutic Innovation & Regulatory Science·Makoto TanakaKatsura Tsukamoto
Dec 21, 2018·Journal of Medical Internet Research·Ching LamZhanfeng Cui
Jun 21, 2018·Clinical Pharmacology and Therapeutics·Philippe SerranoChristine Mayer-Nicolai
Oct 23, 2019·Immunotherapy·Jacqueline R HwangTimothy Craig
Dec 12, 2019·Future Oncology·Pan PantziarkaLydie Meheus
Feb 5, 2021·Pharmaceutical Medicine·Magdalena BujarLawrence Liberti
Jan 12, 2021·Frontiers in Bioengineering and Biotechnology·Ryosuke KurauchiTatsuya Ito
Mar 12, 2021·British Journal of Clinical Pharmacology·Mototsugu TanakaMutsuhiro Ikuma
Jun 6, 2020·Health Policy·Tingting QiuMondher Toumi
Dec 18, 2021·Journal of Medical Economics·Mihajlo JakovljevicTakuma Sugahara